p27在骨巨细胞瘤中的表达及临床意义  被引量:3

P27 PROTEIN EXPRESSION IN GIANT CELL TUMOR OF BONE AND ITS CLINICAL SIGNIFICANCE

在线阅读下载全文

作  者:郭成学[1] 丁力[1] 王桂琴[1] 王勤[1] 

机构地区:[1]河南省郑州市骨科医院,450052

出  处:《中医正骨》2006年第1期12-13,共2页The Journal of Traditional Chinese Orthopedics and Traumatology

摘  要:为探讨p27蛋白在骨巨细胞瘤中的表达及其与预后的关系。对应用免疫组化SP法检测的75例骨巨细胞瘤标本进行了病理分级和(疗效)预后分组对比分析和相关研究。结果显示病理分级中,p27蛋白高表达(++)率Ⅰ级者占61.3%,Ⅱ级者占44.4%,Ⅲ级者占12.5%,各组之间相比,Ⅰ级与Ⅲ级之间强阳性率相比有显著性差异(P<0.05),其他各组之间相比,均无显著性差异(P>0.05);在预后分组中治愈组、复发组及转移组比较,p27蛋白表达治愈组强阳性率(73.3%)与复发组强阳性率(8.0%)之间相比有极显著性差异(P<0.01),治愈组与转移组强阳性率(20.0%)之间相比,有极显著性差异(P<0.01),在复发组与转移组中,p27蛋白表达基本相似,二者之间强阳性率相比,无显著性差异(P>0.05)。表明p27蛋白减少或缺失,与病理形态恶性及复发、转移密切相关,是复发转移的重要阴性预测因子。In order to study the expression of p27 protein in giant cell tumor of bone and its relation to the prognosis, comparative analysis and related study were made on the pathological grading and prognostic grouping of 75 samples of giant cell tumor detected by the immunohistochemical S-P method. The results showed: (1) in the pathological grading, the high p27 protein expression rates (++) included grade I with 61.3 %, grade II with 44.4 % and grade III with 12.5 %, the inter-group comparison showed a significant difference between grade I and grade III in the high positive rates (P < 0.05) but no significant difference among other groups (P > 0.05); (2) in the prognostic grouping, the high positive rates of p27 protein expression included 73.3 % of the cured group versus 8.0 % of the recurrent group and 20 % of the metastatic group (P < 0.01), the p27 protein expression of the recurrent group was basically similar to that of the metastatic group with no significant difference (P > 0.05), suggesting that the decrease or absence of p27 protein is closely related to the malignant pathological morphology, recurrence and metastasis.

关 键 词:骨巨细胞瘤/病理生理学 免疫组织化学 P27蛋白 临床研究 

分 类 号:R738.1[医药卫生—肿瘤]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象